NCT02628405 - R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 20, 2016

Primary Completion Date

September 24, 2021

Study Completion Date

December 20, 2025

Conditions

Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Primary Mediastinal (Thymic) Large B-Cell LymphomaRecurrent Transformed Non-Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Primary Mediastinal (Thymic) Large B-Cell LymphomaRefractory Transformed Non-Hodgkin Lymphoma

Interventions

DRUG

Carboplatin

Given IV

DRUG

Etoposide

Given IV

DRUG

Ifosfamide

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Lenalidomide

Given PO

BIOLOGICAL

Rituximab

Given IV

Trial Locations (12)

13210

State University of New York Upstate Medical University, Syracuse

51101

Siouxland Regional Cancer Center, Sioux City

52242

University of Iowa/Holden Comprehensive Cancer Center, Iowa City

54449

Marshfield Medical Center-Marshfield, Marshfield

55416

Metro Minnesota Community Oncology Research Consortium, Saint Louis Park

55905

Mayo Clinic in Rochester, Rochester

56303

Coborn Cancer Center at Saint Cloud Hospital, Saint Cloud

57701

Rapid City Regional Hospital, Rapid City

61801

Carle Cancer Center NCI Community Oncology Research Program, Urbana

32224-9980

Mayo Clinic in Florida, Jacksonville

03756

Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon

07601

Hackensack University Medical Center, Hackensack

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Academic and Community Cancer Research United

OTHER